Observational studyWorld journal of gastroenterology2019
Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
Observational study in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Systemic treatment for recurrence of hepatocellular carcinoma after liver transplantation: a case report.Journal of gastrointestinal oncology · 2025Article
- Evaluation of Combined Lipiodol and Epirubicin-Loaded Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
- Geographic diversity of human liver cancers mirrors global social inequalities.Frontiers in oncology · 2025Review
- Screening, Surveillance, and Management of Hepatocellular Carcinoma During the COVID-19 Pandemic: a Narrative Review.Journal of gastrointestinal cancer · 2023Review
- Sorafenib as first-line treatment for patients with primary hepatocellular carcinoma: an outcome evaluation.The Journal of international medical research · 2023Article
- A Decreased Response to Resistin in Mononuclear Leukocytes Contributes to Oxidative Stress in Nonalcoholic Fatty Liver Disease.Digestive diseases and sciences · 2022Article
- Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2022Article
- Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups?World journal of gastroenterology · 2021Review
- Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients.Frontiers in pharmacology · 2021Article
- Efficacy of Sorafenib Combined with Interventional Therapy on Primary Liver Cancer Patients and Its Effect on Serum AFP, VEGF, and GGT.Journal of oncology · 2021Article
- Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors.World journal of gastroenterology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) represents the sixteenth most frequent cancer in Argentina. The rise of new therapeutic modalities in intermediate-advanced HCC opens up a new paradigm for the treatment of HCC.
aimTo describe real-life treatments performed in patients with intermediate-advanced HCC before the approval of new systemic options.
methodsThis longitudinal observational cohort study was conducted between 2009 and 2016 in 14 different regional hospitals from Argentina. Included subjects had intermediate-advanced Barcelona Clinic Liver Cancer (BCLC) HCC stages (BCLC B to D). Primary end point analyzed was survival, which was assessed for each BCLC stage from the date of treatment until last patient follow-up or death. Kaplan Meier survival curves and Cox regression analysis were performed, with hazard ratios (HR) calculations and 95% confidence intervals (95%CI).
resultsFrom 327 HCC patients, 41% were BCLC stage B, 20% stage C and 39% stage D. Corresponding median survival were 15 mo (IQR 5-26 mo), 5 mo (IQR 2-13 mo) and 3 mo (IQR 1-13 mo) (
conclusionIn this real setting, our results were lower than expected. This highlights unmet needs in Argentina, prior to the introduction of new treatments for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.